Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,126.06
(
1.20%
)
US TECH 100
25,958.80
(
1.33%
)
Dow Jones
49,447.43
(
1.88%
)
Brent Oil
92.38
(
-0.30%
)
Bitcoin
74,223.54
(
0.49%
)
News Focus
News Focus
Post# of 257426
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122876
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 186454

Thursday, 01/22/2015 7:37:35 PM

Thursday, January 22, 2015 7:37:35 PM

Post# of 257426
Agree on both counts: Sovaldi + Olysio (no NS5a) is the most medically justifiably second-line regimen for Harvoni failures, but payers won’t go for that. So, that leaves V-Pak or Sovaldi+IFN/RBV, which is no contest.

p.s. I question whether JNJ will continue marketing Olysio in the US market for more than a couple of quarters.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today